Why the study?
Does adding antiplatelet therapy to oral anticoagulation reduce systemic embolism or death in patients with prosthetic heart valves?
Does adding antiplatelet therapy to oral anticoagulation reduce systemic embolism or death in patients with prosthetic heart valves?
Adding antiplatelet therapy to oral anticoagulation in high-risk prosthetic heart valve patients reduces systemic embolism and death at the cost of increased major bleeding.
No takes yet. Share an insight, caveat, or question.
Supports dual antithrombotic therapy in prosthetic valves with net benefit assessment; confirms RCT evidence on embolism reduction versus bleeding.
Massel et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: